Oncology Drug Snapshot: Axitinib (Inlyta)

Article

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!
Recent Videos
Sven Moller-Tank, PhD, a senior director at Regeneron
Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Related Content
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel

Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel

Noah Stansfield
August 5th 2025
Article

The patient’s death was attributed to antiCD52 monoclonal antibody ALLO-647 rather than to cema-cel itself.

ImmunoLogic Episode 5

ImmunoLogic, Episode 5: "Tumor Infiltrators and Triumphs: The Evolution of TIL Therapy" With Michael T. Lotze, MD

Joseph A. Fraietta, PhD;Michael T. Lotze, MD;Noah Stansfield;Matt Hoffman
August 5th 2025
Podcast

In episode 5 of ImmunoLogic, Michael T. Lotze, MD, discusses the evolution and future of tumor-infiltrating lymphocyte therapies.

FDA Activity Recap: July 2025 Features Multiple CRLs, RMAT Designation, and More

FDA Activity Recap: July 2025 Features Multiple CRLs, RMAT Designation, and More

Noah Stansfield
August 5th 2025
Article

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio
August 5th 2025
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Roche Slammed With Negative EMA CHMP Opinion for Sarepta’s DMD Gene Therapy Elevidys

Roche Slammed With Negative EMA CHMP Opinion for Sarepta’s DMD Gene Therapy Elevidys

Noah Stansfield
August 5th 2025
Article

The opinion recommends against conditional marketing authorization for patients who are ambulatory.

Cokey Nguyen, PhD, the president and chief executive officer of Atara

FDA Accepts Atara Biotherapeutics’ Resubmission of BLA for Tabelecleucel

Noah Stansfield
August 5th 2025
Article

Notably, the BLA resubmission was accepted with priority review and the PDUFA target action date has been set for January 10, 2026.

© 2025 MJH Life Sciences

All rights reserved.